although
antivir
drug
avail
treatment
influenza
infect
urgent
requir
develop
new
antivir
drug
regard
emerg
drugresist
virus
nucleoprotein
np
conserv
among
influenza
virus
iav
cellular
equival
therefor
np
ideal
target
develop
new
iav
inhibitor
studi
identifi
novel
antiinfluenza
compound
librari
compound
use
cellbas
influenza
infect
assay
found
inhibit
replic
influenza
viru
strain
vitro
ic
rang
lm
furthermor
inhibit
polymeras
activ
specif
impair
nuclear
export
np
investig
indic
bind
nuclear
export
signal
domain
dimer
interfac
np
pocket
also
protect
mice
challeng
lethal
dose
apr
viru
effect
reliev
lung
histopatholog
chang
well
strongli
inhibit
express
proinflammatori
cytokineschemokin
without
induc
toxic
effect
mice
result
suggest
promis
antiinfluenza
compound
investig
use
strategi
iav
futur
influenza
viru
iav
import
human
viral
pathogen
respons
period
human
pandem
well
season
influenza
result
substanti
human
morbid
mortal
worldwid
financi
burden
annual
vaccin
current
avail
control
infect
human
howev
mutat
haemagglutinin
ha
neuraminidas
na
protein
circul
virus
easili
escap
surveil
host
immun
system
specif
antivir
drug
avail
prophylaxi
therapeut
treatment
individu
infect
iav
two
class
food
drug
administr
fda
approv
antiinfluenza
drug
current
use
treatment
iav
infect
includ
na
inhibitor
oseltamivir
zanamivir
matrix
protein
ion
channel
inhibitor
amantadin
rimantadin
howev
resist
develop
seriou
problem
antivir
drug
particularli
target
viral
protein
continu
undergo
high
frequenc
antigen
drift
human
influenza
virus
includ
pandem
current
resist
amantadinerimantadin
oseltamivir
therefor
identif
novel
antivir
target
develop
antivir
drug
treatment
influenza
viru
infect
imper
viral
nucleoprotein
np
influenza
viru
recent
identifi
target
develop
antivir
drug
influenza
np
major
compon
viral
ribonucleoprotein
vrnp
complex
abundantli
express
infect
multipl
function
vrnp
complex
util
nuclear
local
signal
nlss
within
np
nuclear
import
cellular
importinabdepend
nuclear
import
pathway
also
support
previou
report
late
stage
infect
np
nuclear
export
protein
nep
matrix
protein
mediat
transport
newli
assembl
vrnp
complex
nucleu
cytoplasm
overal
np
sever
conform
activ
conserv
among
influenza
virus
cellular
equival
thu
np
ideal
target
develop
commerci
antiinfluenza
drug
studi
aim
identifi
new
antiinfluenza
compound
highthroughput
screen
librari
consist
compound
use
cellbas
infect
assay
identifi
compound
inhibit
iav
replic
show
low
cell
toxic
vitro
vivo
shown
inhibit
viral
polymeras
activ
influenza
virus
nuclear
export
np
furthermor
dock
analysi
surfac
plasmon
reson
spr
analysi
coimmunoprecipit
assay
show
bind
small
pocket
structur
np
molecul
chemic
librari
structur
divers
small
molecul
compound
chemdiv
purchas
j
k
chemic
compani
shanghai
china
puriti
synthes
institut
medicin
chemistri
sysu
stock
dimethyl
sulphoxid
dmso
oseltamivir
phosphat
os
purchas
selleck
compani
shanghai
china
stock
solut
prepar
dmso
leptomycin
b
lmb
purchas
cell
signal
technolog
beverli
usa
dissolv
ethanol
etoh
lipopolysaccharid
lp
purchas
sigmaaldrich
st
loui
mo
usa
stock
solut
prepar
water
human
lung
carcinoma
cell
human
embryon
kidney
cell
madindarbi
canin
kidney
mdck
cell
maintain
dulbecco
modifi
eagl
medium
dmem
gibco
lo
angel
ca
usa
supplement
foetal
bovin
serum
fb
gibco
penicillinstreptomycin
co
influenza
viru
viru
viru
use
viru
purchas
american
type
cultur
collect
atcc
viru
stock
prepar
previous
describ
eight
fragment
influenza
viru
vrnp
gene
fragment
viru
synthes
invitrogen
fragment
viru
virus
clone
vector
separ
previous
describ
ctermin
hatag
flagtag
npexpress
plasmid
mutant
npexpress
plasmid
deriv
influenza
apr
viru
clone
vector
separ
antibodi
use
report
includ
antiha
mous
monoclon
mbl
japan
antiflag
rabbit
polyclon
mbl
antigapdh
rabbit
polyclon
proteintech
group
chicago
il
usa
antinp
rabbit
polyclon
abcam
cambridg
usa
antilamin
rabbit
polyclon
proteintech
group
mous
monoclon
bd
bioscienc
san
jose
ca
usa
antibodi
rabbit
polyclon
sino
biolog
china
influenza
viru
viru
rescu
use
eight
plasmidbas
revers
genet
system
describ
previous
madindarbi
canin
kidney
mdck
cell
seed
onto
plate
incub
dmem
contain
synthes
librari
compound
use
tecan
freedom
tecan
annedorf
schweiz
final
concentr
lm
column
receiv
dmso
instead
compound
cell
infect
influenza
viru
multipl
infect
moi
hr
postinfect
pi
celltit
aqueou
one
solut
reagent
electron
coupl
reagent
ad
well
recommend
manufactur
cultur
hr
cell
viabil
determin
measur
absorb
wavelength
nm
screen
assay
perform
twice
studi
plaqu
assay
antivir
activ
antiinfluenza
viru
activ
test
accord
previou
report
viru
titr
determin
plaqu
assay
mdck
cell
previous
describ
briefli
cell
infect
influenza
viru
moi
hr
pi
medium
replac
dmem
contain
bsa
lgml
tpcktrypsin
supernat
collect
hr
pi
measur
viru
titr
viru
titr
determin
plaqu
assay
mdck
cell
mdck
cell
seed
plate
use
infect
cell
grown
confluenc
mdck
cell
wash
phosphatebuff
salin
pb
infect
seri
dilut
virus
hr
co
viru
inocula
remov
cell
wash
pb
overlaid
agaros
medium
dmem
contain
bsa
lgml
tpcktrypsin
lowmeltingpoint
agaros
sigmaaldrich
plate
settl
min
agaros
medium
becam
solid
follow
cultur
upsid
cell
cultur
hr
visibl
plaqu
count
inhibitori
concentr
determin
count
number
plaqu
cell
toxic
assay
determin
mt
assay
accord
manufactur
instruct
promega
madison
wi
previous
describ
data
shown
mean
aestandard
deviat
sd
three
independ
experi
influenza
viru
minigenom
system
polymeras
activ
influenza
viru
minigenom
system
perform
previous
describ
data
shown
mean
ae
sd
three
independ
experi
cell
lyse
icecold
lysi
buffer
min
lysat
collect
separ
sdspage
previous
describ
band
immunoblot
indic
primari
antibodi
irdy
secondari
antibodi
licor
lincoln
ne
usa
visual
odyssey
infrar
imag
system
licor
rel
protein
express
level
analys
use
softwar
provid
odyssey
system
human
cell
seed
dish
transfect
variou
plasmid
indic
cell
untreat
treat
differ
amount
hr
pt
hr
pt
cell
lyse
icecold
lysi
buffer
lysat
taken
input
control
remain
lysat
incub
antiha
agaros
bead
hr
bead
wash
three
time
icecold
lysi
buffer
follow
western
blot
immunofluoresc
assay
ifa
perform
previous
describ
briefli
cell
fix
paraformaldehyd
permeabil
triton
subsequ
block
bsa
block
solut
stain
primari
antibodi
secondari
antibodi
cell
nuclei
stain
dapi
reagent
invitrogen
carlsbad
ca
usa
imag
obtain
leica
laser
scan
microscop
use
leica
softwar
wetzlar
germani
human
cell
transfect
nphaexpress
plasmid
untreat
treat
cell
harvest
wash
pb
hr
pt
fraction
cytoplasm
nuclear
compon
perform
accord
manufactur
instruct
pari
millipor
usa
previous
describ
cell
transfect
aidgfp
differ
treatment
collect
fix
formaldehyd
analys
bd
lsr
fortessa
tm
cell
analyz
accord
manufactur
protocol
bd
previous
describ
crystal
structur
influenza
viru
nucleoprotein
download
rcsb
protein
data
bank
pdb
code
resolut
np
bind
assess
use
dock
ligand
receptor
structur
construct
use
ucsf
chimera
program
util
conduct
semiflex
dock
differ
orient
gener
van
der
waal
electrostat
interact
obtain
ligand
bind
site
use
calcul
grid
score
use
molecular
visual
tool
pymol
pymol
molecular
graphic
system
version
seattl
usa
gener
surfac
np
help
spot
bind
site
interfac
np
assay
perform
use
biacor
instrument
ge
healthcar
amersham
uk
previous
describ
modif
biacor
sensor
chip
amin
coupl
kit
purchas
ge
healthcar
optim
ph
nphi
immobil
ph
first
determin
censor
chip
activ
inject
nphi
mgml
mm
acet
buffer
ph
min
residu
activ
group
surfac
block
inject
ethanolamin
hcl
min
differ
amount
dilut
dmso
inject
min
anim
experi
approv
ethic
committe
zhongshan
school
medicin
zssom
laboratori
anim
care
carri
strict
accord
guidelin
regul
laboratori
anim
center
zssom
sysu
guangzhou
china
assur
number
mice
studi
provid
via
standard
pellet
feed
water
procedur
perform
anaesthesia
induc
isofluran
rwd
life
scienc
co
ltd
shenzhen
china
treatment
effort
made
minim
suffer
mice
kill
rapid
last
weight
loss
loss
bodi
weight
day
observ
vivo
antivir
activ
assay
dissolv
dmso
dilut
corn
oil
sigmaaldrich
final
concentr
mgml
dmso
dilut
corn
oil
taken
control
male
balbc
mice
approxim
g
use
experi
mice
intranas
infect
ten
lethal
dose
ld
intraperiton
inject
twice
daili
mgkg
day
begin
hr
infect
respect
coadministr
experi
mice
intraperiton
coadminist
given
monotherapi
mgkg
mgkg
oseltamivir
phosphat
twice
daili
day
begin
hr
infect
respect
eight
mice
per
treatment
group
test
bodi
weight
surviv
rate
group
measur
daili
parallel
experi
five
mice
group
kill
day
pi
lung
remov
determin
viral
titr
use
plaqu
assay
experi
repeat
triplic
differ
bodi
weight
lung
viral
titr
group
compar
control
use
oneway
anova
analysi
surviv
rate
analys
logrank
test
data
consid
signific
p
p
p
total
rna
isol
qrtpcr
perform
previous
describ
specif
primer
target
gene
tnfa
gapdh
housekeep
control
mice
design
use
primer
base
correspond
gene
sequenc
protein
primer
sequenc
follow
data
shown
mean
ae
sd
three
independ
experi
half
lung
liver
spleen
kidney
heart
mous
fix
formalin
embed
paraffin
stain
haematoxylin
eosin
h
e
histolog
analysi
slide
random
read
blindli
examin
tissu
damag
inflammatori
cellular
infiltr
lung
patholog
score
rang
previou
report
data
analys
use
graphpad
prism
softwar
la
jolla
ca
usa
twotail
student
ttest
oneway
anova
logrank
test
use
determin
signific
statist
data
data
consid
signific
p
p
p
discov
novel
antiinfluenza
compound
mdck
cellbas
influenza
infect
highthroughput
screen
perform
briefli
chemic
librari
structur
divers
small
molecul
compound
lm
appli
screen
mdck
cell
infect
viru
multipl
infect
moi
pfu
perform
doserespons
assay
among
hit
compound
identifi
seven
compound
exert
inhibitori
effect
concentr
lm
among
antiinfluenza
hit
compound
show
highest
potenc
influenza
viru
plaqu
reduct
assay
pra
mdck
cell
infect
viru
chemic
structur
compound
shown
figur
use
plaqu
assay
inhibitori
concentr
ic
mdck
cell
lower
lm
fig
show
similar
level
antivir
activ
differ
iav
subtyp
includ
viru
ic
ae
lm
viru
ic
ae
lm
fig
furthermor
low
toxic
mdck
cell
cytotox
concentr
cc
compound
lm
fig
togeth
result
show
compound
significantli
inhibit
replic
iav
confirm
inhibitori
effect
replic
iav
examin
effect
viral
protein
synthesi
observ
signific
dosedepend
decreas
viral
protein
synthesi
treatment
compar
control
dimethyl
sulphoxid
dmso
fig
furthermor
western
blot
analysi
show
level
viral
protein
decreas
compar
control
earli
hr
pi
fig
impli
inhibit
replic
influenza
viru
explor
target
explor
inhibitori
activ
two
addit
assay
pseudotyp
viru
express
influenza
haemagglutinin
ha
dualluciferas
minigenom
system
found
inhibit
entri
iav
pseudotyp
viru
report
system
data
shown
dualluciferas
minigenom
system
show
significantli
inhibit
viral
rna
polymeras
activ
dosedepend
manner
fig
also
effect
decreas
polymeras
activ
influenza
strain
fig
result
indic
inhibit
activ
vrnp
complex
previou
studi
demonstr
block
vrnp
nuclear
transport
impair
activ
vrnp
complex
confirm
inhibitori
effect
viral
polymeras
activ
infect
cell
perform
immunofluoresc
assay
ifa
examin
whether
affect
nuclear
transport
vrnp
influenza
viru
np
major
compon
vrnp
complex
locat
np
infect
cell
repres
locat
vrnp
complex
accordingli
reduct
viral
np
protein
express
also
detect
ifa
assay
fig
found
np
cell
treat
dmso
neg
control
predominantli
locat
cytoplasm
hr
pi
howev
treat
np
locat
nucleu
fig
indic
presenc
vrnp
complex
abl
enter
nucleu
export
cytoplasm
afterward
retent
np
nucleu
obviou
higher
dose
result
show
affect
nucleocytoplasm
distribut
influenza
viru
vrnp
complex
infect
influenza
viru
np
nuclear
shuttl
protein
contain
nuclear
local
signal
nlss
nuclear
export
signal
ness
among
vrnp
complex
compon
np
known
ne
therefor
retent
vrnp
complex
nucleu
might
due
disrupt
nuclear
export
np
human
cell
transfect
nphaexpress
plasmid
treat
differ
amount
fix
hr
pt
follow
immunofluoresc
use
antiha
antibodi
red
nucleu
stain
dapi
blue
scale
bar
lm
b
quantit
analysi
nucleocytoplasm
distribut
np
least
cell
lm
group
three
independ
assay
score
n
predominantli
nuclear
n
c
nuclear
cytoplasm
c
predominantli
cytoplasm
data
express
mean
ae
sd
three
independ
experi
differ
group
dmso
test
use
student
ttest
p
p
p
c
cell
transfect
npha
treat
dmso
control
separ
cytoplasm
c
nuclear
n
fraction
fraction
examin
western
blot
elucid
hypothesi
investig
effect
nuclear
export
np
ifa
inde
found
np
mainli
detect
cytoplasm
hr
posttransfect
pt
absenc
mostli
retain
nucleu
cytoplasm
distribut
np
depend
dose
fig
subcellular
local
np
presenc
lm
compound
group
score
use
random
field
view
triplic
result
demonstr
np
locat
nucleu
presenc
fig
accordingli
repeat
assay
use
nuclearcytoplasm
fraction
lower
cytoplasm
ratio
np
observ
treatment
fig
howev
local
anoth
major
protein
vrnp
complex
alter
treatment
fig
among
vrnp
complex
protein
np
known
ne
howev
iav
absenc
nep
export
np
nucleu
therefor
indic
nep
necessari
nuclear
export
vrnp
complex
thu
analys
locat
nep
treatment
found
nuclear
locat
nep
affect
treatment
fig
indic
effect
specif
nuclear
export
np
iav
adapt
cellular
nuclear
export
pathway
transport
vrnp
complex
nucleu
cytoplasm
nucleoprotein
np
retain
nucleu
b
effect
distribut
nep
cell
human
cell
transfect
plasmid
nephaexpress
plasmid
b
treat
dmso
lm
hr
pt
fix
hr
pt
follow
immunofluoresc
use
antiha
antibodi
red
c
effect
nuclear
export
aid
human
cell
transfect
aidgfpexpress
plasmid
treat
dmso
lm
hr
pt
fix
hr
pt
follow
fluoresc
microscopi
analysi
scale
bar
lm
group
score
use
random
field
view
triplic
affect
aidgfp
nuclear
stabil
human
cell
transfect
aidgfpexpress
plasmid
treat
dmso
lm
lmb
nm
hr
pt
fix
hr
pt
follow
fac
analysi
data
shown
mean
ae
sd
three
independ
experi
p
student
ttest
presenc
specif
inhibitor
leptomycin
b
lmb
exclud
possibl
lmblike
inhibitor
examin
effect
nuclear
export
activationinduc
deaminas
aid
wellknown
host
protein
export
nucleu
via
nuclear
export
pathway
figur
show
inhibit
nuclear
export
aidgfp
wherea
lmb
treatment
aidgfp
unstabl
nucleu
lmb
treatment
result
degrad
aidgfp
fig
howev
treatment
affect
express
aidgfp
togeth
result
suggest
specif
target
np
transport
system
confirm
whether
np
direct
molecular
target
util
publish
crystal
structur
influenza
np
protein
data
bank
pdb
silico
dock
studi
unbias
predict
dock
analysi
search
potenti
dock
site
within
entir
np
monom
five
potenti
bind
site
identifi
fig
base
highest
bind
free
energi
bind
site
within
np
select
analysi
configur
best
bind
score
dg
kcalmol
also
identifi
use
studi
fig
two
amino
acid
residu
hydrogen
bond
play
major
role
bind
np
fig
confirm
accuraci
bind
model
surfac
plasmon
reson
spr
experi
util
examin
whether
bind
wildtyp
mutant
np
protein
harbour
alanin
substitut
within
potenti
bind
site
mutant
spr
assay
indic
dosedepend
bound
wildtyp
nphi
mutant
nphi
kd
valu
lmoll
respect
fig
although
remain
bind
histag
mutant
np
protein
bind
affin
significantli
lower
wildtyp
np
protein
therebi
indic
two
residu
play
critic
role
interact
np
result
suggest
bind
np
mainli
amino
acid
residu
predict
silico
dock
analysi
bind
region
np
aa
involv
nuclear
export
np
therebi
indic
mechan
underli
nuclear
export
np
previou
studi
shown
nuclear
export
mediat
wherea
investig
whether
inhibitori
effect
nuclear
export
np
depend
nuclear
transport
pathway
examin
bind
endogen
np
presenc
absenc
bind
np
inhibit
dosedepend
manner
fig
result
indic
inhibit
bind
np
interact
ne
domain
np
addit
np
amino
acid
involv
interact
dock
model
show
partial
bound
amino
acid
involv
np
dimer
domain
examin
whether
induc
dissoci
npnp
homooligom
perform
coip
assay
incorpor
np
protein
fuse
differ
tag
previou
report
absenc
npflag
abl
bind
ha
agaros
bead
coupl
npha
fig
howev
inhibit
bind
npflag
npha
dosedepend
manner
suggest
also
inhibit
npnp
interact
taken
togeth
result
demonstr
inhibit
function
domain
oligomer
np
nprna
interact
vivo
test
test
vivo
efficaci
iav
infect
mice
inocul
ld
intraperiton
inject
daili
differ
dose
mgkg
twice
per
day
five
day
begin
hr
infect
respect
fig
treatment
appar
protect
mice
influenzainduc
morbid
lethal
fig
c
parallel
experi
mice
kill
group
pi
lung
isol
use
determin
viru
titr
plaqu
assay
fig
e
viru
load
lung
mice
significantli
lower
control
group
moreov
oseltamivir
phosphat
coadministr
investig
antivir
activ
treat
togeth
oseltamivir
phosphat
although
less
effect
protect
mice
influenza
vivo
compar
oseltamivir
phosphat
coadministr
oseltamivir
phosphat
result
even
lower
degre
weight
loss
higher
surviv
rate
treat
oseltamivir
phosphat
alon
fig
g
result
support
hypothesi
mechan
oseltamivir
phosphat
highli
variabl
better
vivo
effect
observ
administ
combin
coadministr
oseltamivir
phosphat
also
significantli
reduc
viral
load
lung
fig
result
show
effect
protect
mice
influenza
infect
vivo
fig
effect
iav
replic
vivo
ac
mice
infect
intranas
ld
influenza
viru
differ
amount
intraperiton
inject
balbc
mice
hr
viru
exposur
twice
per
day
day
begin
day
infect
dmso
dilut
corn
oil
use
neg
control
eight
mice
per
treatment
group
test
bodi
weight
mice
group
monitor
daili
b
surviv
rate
also
calcul
c
bodi
weight
day
set
group
mgkg
p
group
mgkg
p
p
p
mgkg
p
p
p
student
ttest
surviv
rate
group
compar
control
use
logrank
test
p
p
de
five
mice
group
kill
day
pi
lung
collect
determin
viral
titr
data
express
mean
ae
sd
fh
antivir
effect
coadministr
oseltamivir
phosphat
vivo
mgkg
oseltamivir
phosphat
os
mgkg
intraperiton
coadminist
given
monotherapi
balb
c
mice
twice
per
day
day
begin
day
infect
respect
bodi
weight
mice
group
monitor
daili
f
surviv
rate
also
calcul
g
bodi
weight
day
set
group
mgkg
p
p
mgkg
os
p
p
p
group
coadministr
oseltamivir
phosphat
p
p
p
bodi
weight
group
compar
control
group
use
oneway
anova
surviv
rate
group
compar
control
use
logrank
test
p
p
p
parallel
experi
lung
titr
group
analys
day
pi
h
differ
group
control
test
use
oneway
anova
p
p
p
experi
repeat
three
time
bodi
weight
chang
surviv
rate
group
show
singl
experi
influenza
viru
infect
caus
sever
lung
patholog
associ
acut
lung
inflamm
exacerb
partli
host
immun
respons
viru
infect
downregul
proinflammatori
cytokineschemokin
imped
influenza
virusassoci
pathogenesi
mice
collect
total
rna
extract
mrna
level
cytokin
involv
promot
inflamm
report
play
import
role
sever
iav
infect
lung
significantli
decreas
mice
compar
untreat
mice
fig
howev
treat
mice
lipopolysaccharid
lp
activ
alter
express
tnfa
lung
indict
effect
express
proinflammatori
cytokin
absenc
infect
fig
result
show
reduc
express
proinflammatori
cytokin
associ
influenza
viru
infect
parallel
experi
lung
collect
day
pi
stain
h
e
histolog
evalu
treatment
fig
antiinflammatori
activ
vivo
rel
mrna
express
cytokineschemokin
test
three
mice
timepoint
group
kill
day
pi
lung
collect
analysi
mrna
express
proinflammatori
cytokineschemokin
respect
influenza
ha
taken
posit
control
experi
b
mice
inject
mgkg
lp
togeth
without
monitor
rel
mrna
express
day
treatment
data
express
mean
ae
sd
p
student
ttest
ch
effect
attenu
lung
patholog
influenzainfect
mice
lung
sampl
subject
quantit
score
lung
patholog
c
data
express
mean
ae
sd
p
p
student
ttest
mice
group
four
mice
group
kill
day
pi
lung
collect
stain
h
e
use
histopatholog
analysi
arrow
infiltr
inflammatori
cell
arrow
b
alveolar
wall
thicken
scale
bar
lm
allevi
inflamm
interstiti
epithelium
thicken
induc
iav
infect
fig
observ
impli
probabl
limit
spread
viru
lung
therebi
allevi
inflamm
line
figur
result
also
indic
inhibit
replic
iav
vivo
turn
allevi
inflammatori
level
patholog
induc
iav
overal
find
suggest
potent
antiinflammatori
effect
host
intens
immun
respons
induc
iav
present
studi
identifi
novel
compound
effici
inhibit
replic
influenza
viru
vitro
vivo
effici
protect
cell
differ
subtyp
influenza
viru
particular
abl
inhibit
replic
viru
rel
low
concentr
ic
ae
nm
vitro
furthermor
vivo
data
indic
reduc
express
proinflammatori
cytokineschemokin
allevi
infiltr
inflamm
lung
caus
iav
infect
also
increas
surviv
rate
mice
prevent
bodi
weight
loss
due
iav
infect
result
suggest
effect
inhibit
iav
replic
reduc
viral
titr
vitro
vivo
turn
allevi
patholog
induc
iav
find
suggest
potent
antiinflammatori
effect
host
intens
immun
respons
induc
iav
therebi
render
promis
lead
compound
treatment
sever
influenza
vivo
coadministr
oseltamivir
phosphat
augment
antivir
effect
suggest
inhibit
viral
replic
via
new
mechan
differ
oseltamivir
phosphat
investig
indic
block
nuclear
transport
vrnp
complex
nucleu
target
nuclear
export
np
three
ness
identifi
within
np
export
via
independ
transport
pathway
wherea
export
via
depend
bind
therefor
nuclear
retent
np
induc
may
due
disrupt
follow
pathway
target
within
np
ii
target
within
np
block
interact
np
iii
target
associ
protein
exclud
direct
target
util
aidgfpexpress
plasmid
experi
aid
classic
host
protein
transport
nucleu
mainli
mediat
pathway
distribut
aidgfp
affect
wherea
classic
small
molecul
inhibitor
lmb
block
nuclear
export
aid
therefor
directli
inhibit
transport
pathway
lmb
explor
particular
bind
site
within
np
dock
analysi
incorpor
structur
within
np
perform
result
show
potenti
bind
site
within
np
small
pocket
includ
line
bind
model
investig
prove
directli
bind
np
disrupt
interact
np
moreov
dock
analysi
spr
assay
indic
aa
np
anoth
import
bind
site
line
result
inhibit
npnp
interact
reduc
polymeras
activ
impair
protein
synthesi
iav
taken
togeth
result
strongli
support
theori
np
target
drug
resist
seriou
problem
associ
influenza
treatment
caus
high
antigen
drift
shift
rate
discoveri
new
target
thu
focu
develop
new
antiinfluenza
therapeut
sequenc
analysi
indic
np
wellconserv
protein
among
differ
strain
iav
furthermor
target
site
within
np
highli
conserv
conserv
therebi
indic
broadli
inhibitori
potenc
variou
iav
strain
includ
replic
subtyp
polymeras
activ
subtyp
altern
challeng
drug
design
develop
avoid
occurr
seriou
side
effect
influenza
np
protein
play
crucial
role
viral
life
cycl
activ
assembl
stabil
nuclear
transport
vrnp
complex
reli
function
np
therefor
np
highli
conserv
function
restrict
protein
thu
render
promis
specif
target
antiinfluenza
drug
design
nucleoprotein
np
recent
consid
novel
target
antiinfluenza
drug
design
recent
small
compound
target
function
domain
within
np
identifi
pocket
target
compound
report
surround
three
differ
domain
name
rna
bind
groov
np
dimer
interfac
present
studi
bind
pocket
within
np
studi
similar
base
similar
function
differ
chemic
structur
conclud
bind
pocket
indispens
pocket
np
would
ideal
antivir
target
side
studi
shown
inhibit
iav
replic
vitro
vivo
effici
one
firstgener
hit
compound
identifi
via
highthroughput
screen
could
optim
becom
potent
inhibitor
summari
novel
compound
identifi
high
potenc
inhibit
iav
replic
vitro
vivo
disrupt
distribut
influenza
np
protein
cell
well
block
nuclear
export
np
imped
bind
np
meanwhil
bind
affect
np
dimer
format
impli
compound
multifunct
np
inhibitor
thu
find
present
studi
suggest
promis
antiinfluenza
compound
investig
use
strategi
iav
futur
